Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
I-Mab Biopharma
Pharmaceutical Preparation ManufacturingChinaNASDAQ: IMAB
Last verified 9 months agoi-mabbiopharma.com
I-Mab Biopharma, a leading player in the pharmaceutical preparation manufacturing industry, is headquartered in China (CN) and operates extensively across major regions, including North America and Europe. Founded in 2016, I-Mab has rapidly established itself as a pioneer in the development of innovative biologics, focusing on immuno-oncology and autoimmune diseases.
The company’s core offerings include monoclonal antibodies and other biologic therapies, distinguished by their unique mechanisms of action and potential to address unmet medical needs. I-Mab's commitment to research and development has led to significant milestones, including strategic partnerships and advancements in clinical trials. With a strong market position, I-Mab continues to make notable strides in the biopharmaceutical landscape, aiming to improve patient outcomes globally.
23
DitchCarbon score
-19 vs industry average
I-Mab Biopharma’s score of 23 is lower than 33% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at I-Mab Biopharma?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Very High
Pharmaceutical Preparation Manufacturing is among the most carbon-intensive industries
Industry performance
0.243
02025
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Reported emissions
No reported emissions data is available for I-Mab Biopharma yet.
I-Mab Biopharma's reported carbon emissions
I-Mab Biopharma, a Pharmaceutical Preparation Manufacturing company headquartered in China, has not reported any specific carbon emissions data. The company has not publicly disclosed any reduction targets, including SBTi-validated commitments or participation in initiatives like the Climate Pledge.
Assessing I-Mab Biopharma as a supplier or portfolio company?
- See verified emissions data for over 2 million organizations
- View emissions forecasts for I-Mab Biopharma and the organizations you buy from or invest in
- Get PCAF data quality (DQ) scores, including for private organizations
I-Mab Biopharma’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for I-Mab Biopharma yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
See details
Not active
Carbon Disclosure Project
See details
Not active
The Climate Pledge
See details
Not active
UN Global Compact Climate Champions initiative
See details
Not active
RE 100
See details
Not active
Climate Action 100
See details
Not active
Emissions comparison with industry peers
View similar organisationsCompanyCountryIndustryLast updatedScoreDetails
I-Mab Biopharma9 months ago
23
Need this data for financed emissions?
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more